---
title: "EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286908929.md"
description: "Hoth Therapeutics Inc. plans to rebrand as Rocket One Inc. to focus on AI semiconductor technologies and ultra-low-power AI computing. The board unanimously approved this strategic shift, which includes securing exclusive rights to technologies from Virginia Commonwealth University. The company will maintain its biotechnology operations while addressing AI infrastructure challenges. Hoth's shares fell 9.69% to $0.55 in premarket trading, reflecting a 20.9% decline over the past month."
datetime: "2026-05-19T11:46:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286908929.md)
  - [en](https://longbridge.com/en/news/286908929.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286908929.md)
---

# EXCLUSIVE: Hoth Therapeutics To Rebrand To Pursue AI Chip Technologies

**Hoth Therapeutics Inc.** (NASDAQ:HOTH) on Tuesday said it plans to rebrand as **Rocket One Inc.** and restructure its operations to focus on artificial intelligence infrastructure, semiconductor technologies, and ultra-low-power AI computing through a newly formed wholly owned subsidiary.

The company said the strategic shift was unanimously approved by its board and is aimed at positioning the business within the growing AI semiconductor market.

Hoth added that it secured exclusive rights to AI semiconductor acceleration and spintronic computing technologies developed at Virginia Commonwealth University.

**Read Also: Hoth Therapeutics Early Cancer Trial Succeeds With 100% Patient Response, Cuts Disease Severity By Half**

## Company Targets AI Power And Efficiency Challenges

Under the proposed Rocket One brand, the company intends to focus on technologies designed to address mounting infrastructure pressures tied to artificial intelligence workloads, including power consumption, cooling limitations, memory bottlenecks, and inference latency.

## Rocket One Secures Exclusive Semiconductor Technology Rights

The company said one of the licensed technologies involves a nanomagnetic matrix multiplier intended to function as a hardware accelerator for machine learning and AI applications.

According to Hoth, the architecture is designed to support ultra-low-power AI acceleration, advanced memory efficiency, distributed AI infrastructure, and intelligent autonomous platforms.

The second licensed technology centers on spintronic memory systems that use electron spin rather than conventional charge-based semiconductor methods.

The company said the technology could have applications across defense infrastructure, aerospace systems, radiation-tolerant computing, and orbital AI environments.

## Company To Maintain Biotechnology Operations

Hoth said it plans to continue its biotechnology programs and is evaluating the creation of a separate wholly owned subsidiary for its therapeutic development pipeline.

**HOTH Price Action:** Hoth Therapeutics shares were down 9.69% at $0.55 during premarket trading on Tuesday, according to Benzinga Pro.

Over the past month, HOTH has declined about 20.9% versus a 4.2% rise in the S&P 500 and is down roughly 46% year-to-date compared to the index’s 7.7% gain.

_Image Via Shutterstock_

**Read Also: Michael Burry Says Today's AI Debt Bubble Mirrors The Dot-Com Era**

### Related Stocks

- [HOTH.US](https://longbridge.com/en/quote/HOTH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md)

## Related News & Research

- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [08:00 ETAvance Clinical Receives Frost & Sullivan's 2026 Global Company of the Year Recognition for Excellence in Biotech CRO Leadership](https://longbridge.com/en/news/286094661.md)
- [Silexion Therapeutics Announces Warrant Inducement Financing Agreement](https://longbridge.com/en/news/286622270.md)
- [3 Low Risk Leaders Powering AI, Pulmonary Drugs And Defense](https://longbridge.com/en/news/286654158.md)
- [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md)